FDA OK's trial of Transition's AZD-103.
Alzheimer's Donation
Donate Online Now
.
TORONTO
Transition Therapeutics said Tuesday the U.S. Food and Drug Administration cleared a phase 1 trial of AZD-103 for Alzheimer's.
Transition said it anticipates beginning the trial in September. Healthy volunteers will receive placebo or an escalating dose of AZD-103.
The company said a previous phase 1 trial of AZD-103 announced in April has completed enrollment. The company said in a statement that it plans to release data from the study in "the near future."
A study in a transgenic mouse model of Alzheimer's disease indicated AZD-103 reduced the accumulation of amyloid beta and amyloid beta plaques in the brain. The compound also reduced learning deficits in the mice.
Transition said it anticipates beginning the trial in September. Healthy volunteers will receive placebo or an escalating dose of AZD-103.
The company said a previous phase 1 trial of AZD-103 announced in April has completed enrollment. The company said in a statement that it plans to release data from the study in "the near future."
A study in a transgenic mouse model of Alzheimer's disease indicated AZD-103 reduced the accumulation of amyloid beta and amyloid beta plaques in the brain. The compound also reduced learning deficits in the mice.
posted by Valery Yermalitsky at
5:47 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home